0edf46a2-3dfb-4bae-b642-281e05975bd1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.400
- DNA_REPAIR+0.300
- PANCREAS_BETA_CELLS+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- TGF_BETA_SIGNALING+0.200
- MITOTIC_SPINDLE+0.100
- MTORC1_SIGNALING+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- COMPLEMENT-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.500
- COAGULATION-0.400
- FATTY_ACID_METABOLISM-0.400
- INFLAMMATORY_RESPONSE-0.400
- XENOBIOTIC_METABOLISM-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1AYRM596 | medulloblastoma | — | 0.926 |
| 2 | 25f272b8-11f5-4edc-9c54-f4115fc0a5de | — | — | 0.919 |
| 3 | BS_N6N147BY | Embryonal tumors | — | 0.908 |
| 4 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.901 |
| 5 | BS_D144EJRQ | medulloblastoma | — | 0.901 |
| 6 | SRR10899976 | — | — | 0.900 |
| 7 | 9ca1da07-df79-4bbf-be81-0ef9de95ab0c | — | — | 0.899 |
| 8 | SRR5088819 | — | — | 0.898 |
| 9 | b2e80b2b-559c-424e-837d-fa1de6b912e7 | — | — | 0.895 |
| 10 | BS_HE57E1RP | medulloblastoma | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |